1. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
- Author
-
Eron, Joseph J., primary, Orkin, Chloe, additional, Cunningham, Douglas, additional, Pulido, Federico, additional, Post, Frank A., additional, De Wit, Stéphane, additional, Lathouwers, Erkki, additional, Hufkens, Veerle, additional, Jezorwski, John, additional, Petrovic, Romana, additional, Brown, Kimberley, additional, Van Landuyt, Erika, additional, Opsomer, Magda, additional, De Wit, S., additional, Florence, E., additional, Moutschen, M., additional, Van Wijngaerden, E., additional, Vandekerckhove, L., additional, Vandercam, B., additional, Brunetta, J., additional, Conway, B., additional, Klein, M., additional, Murphy, D., additional, Rachlis, A., additional, Shafran, S., additional, Walmsley, S., additional, Ajana, F., additional, Cotte, L., additional, Girardy, P.-M., additional, Katlama, C., additional, Molina, J.-M., additional, Poizot-Martin, I., additional, Raffi, F., additional, Rey, D., additional, Reynes, J., additional, Teicher, E., additional, Yazdanpanah, Y., additional, Gasiorowski, J., additional, Halota, W., additional, Horban, A., additional, Piekarska, A., additional, Witor, A., additional, Arribas, J.R., additional, Perez-Valero, I., additional, Berenguer, J., additional, Casado, J., additional, Gatell, J.M., additional, Gutierrez, F., additional, Galindo, M.J., additional, Gutierrez, M.D.M., additional, Iribarren, J.A., additional, Knobel, H., additional, Negredo, E., additional, Pineda, J.A., additional, Podzamczer, D., additional, Sogorb, J.Portilla, additional, Pulido, F., additional, Ricart, C., additional, Rivero, A., additional, Santos Gil, I., additional, Blaxhult, A., additional, Flamholc, L., additional, Gisslèn, M., additional, Thalme, A., additional, Fehr, J., additional, Rauch, A., additional, Stoeckle, M., additional, Clarke, A., additional, Gazzard, B.G., additional, Johnson, M.A., additional, Orkin, C., additional, Post, F., additional, Ustianowski, A., additional, Waters, L., additional, Bailey, J., additional, Benson, P., additional, Bhatti, L., additional, Brar, I., additional, Bredeek, U.F., additional, Brinson, C., additional, Crofoot, G., additional, Cunningham, D., additional, DeJesus, E., additional, Dietz, C., additional, Dretler, R., additional, Eron, J., additional, Felizarta, F., additional, Fichtenbaum, C., additional, Gallant, J., additional, Gathe, J., additional, Hagins, D., additional, Henn, S., additional, Henry, W.K., additional, Huhn, G., additional, Jain, M., additional, Lucasti, C., additional, Martorell, C., additional, McDonald, C., additional, Mills, A., additional, Morales-Ramirez, J., additional, Mounzer, K., additional, Nahass, R., additional, Olivet, H., additional, Osiyemi, O., additional, Prelutsky, D., additional, Ramgopal, M., additional, Rashbaum, B., additional, Richmond, G., additional, Ruane, P., additional, Scarsella, A., additional, Scribner, A., additional, Shalit, P., additional, Shamblaw, D., additional, Slim, J., additional, Tashima, K., additional, Voskuhl, G., additional, Ward, D., additional, Wilkin, A., additional, and de Vente, J., additional
- Published
- 2019
- Full Text
- View/download PDF